Eating diets high in ultra-processed foods such as cereal bars, flavored yogurts, and fast food may make it more likely to ...

Deucravacitinib outperformed placebo for treating moderate to severe scalp psoriasis, even among patients with less extensive overall disease.

Risankizumab had greater improvements in skin clearance and quality of life at 16 weeks in patients with psoriasis compared with deucravacitinib.

In the large NutriNet-Santé cohort, people with active psoriasis more frequently belonged to the top tertile of ...